Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novocure shares soar 33% as FDA approves lung cancer treatment
Novocure Ltd (NASDAQ:NVCR) shares soared sharply after the announcement that the FDA had approved Optune Lua, a wearable device designed to treat certain types of lung cancer. The stock surged more than 33% in premarket
NovoCure scoops FDA approval on wearable for metastatic cancer treatment
Optune Lua received US Food and Drug Administration (FDA) approval based on data from the pivotal LUNAR trial, which demonstrated significant median overall survival (OS) improvement.
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for concurrent use with PD-1/PD-L1 i
Novocure shares surge on cancer treatment approval, and other movers
Novocure shares are surging 35% after the company said that the [Food and Drug Administration had approved Optune Lua](
EurekAlert!
17d
FOXM1 and PD-L1 in CDK4/6-MEK resistance in nerve tumors
A new mini review was published in Oncotarget's Volume 15 on September 30, 2024, entitled, “Linking FOXM1 and PD-L1 to CDK4/6 ...
Cure Today
7d
I Still Reflect on My Lung Cancer Treatment Decisions
When I was diagnosed with lung cancer, I didn’t want to receive chemotherapy, especially when I was a good candidate for ...
Targeted Oncology
1d
FDA Oks Optune Lua for Use With PD-1/PD-L1 Inhibitors in Metastatic NSCLC
Following promising results from the phase 3 LUNAR trial, the FDA has approved Optune Lua for use with PD-1/PD-L1 inhibitors ...
emjreviews.com
2d
New Imaging Technique Shows Promise for Personalised Oesophageal Cancer Treatment – UEG Week 2024
Discover a breakthrough imaging technique aimed at improving treatment outcomes for patients with locally advanced ...
BioWorld
21d
Discovery of PD-L1-degrading PROTACs with promising antitumor efficacy
A new series of proteolytic targeting chimeras (PROTACs) was designed by Zhejiang University of Technology scientists based ...
Targeted Oncology
9d
Long-Term Data Confirms Cemiplimab Benefits in High PD-L1 NSCLC
Ana Baramidze, MD, PhD, discussed 5-year follow-up results from the EMPOWER-Lung study evaluating cemiplimab vs chemotherapy ...
The American Journal of Managed Care
1d
FDA Approves Optune Lua Device in NSCLC
Optune Lua creates tumor treating fields to disrupt cancer cell division, and it is used in conjunction with PD-1/PD-L1 ...
Future Market Insights
13d
Global PD-1/PD-L1 Inhibitors Market Set to Reach USD 123.3 Billion by 2033, Growing at a 9.6% CAGR
The global PD-1/PD-L1 inhibitors market is projected to witness remarkable growth over the next decade, with an estimated ...
Armed robbery in Revesby
16d
FOXM1, PD-L1 Linked to CDK4/6-MEK Resistance in Nerve Tumors
We suggest that future therapeutic strategies targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 represent ...
GlobalData on MSN
2d
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint
Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Novocure
Optune Lua
Food and Drug Administration
Exelixis
Pembrolizumab
Feedback